JP2015524474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524474A5 JP2015524474A5 JP2015526649A JP2015526649A JP2015524474A5 JP 2015524474 A5 JP2015524474 A5 JP 2015524474A5 JP 2015526649 A JP2015526649 A JP 2015526649A JP 2015526649 A JP2015526649 A JP 2015526649A JP 2015524474 A5 JP2015524474 A5 JP 2015524474A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- pharmaceutically acceptable
- acceptable carrier
- dose range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679999P | 2012-08-06 | 2012-08-06 | |
| US61/679,999 | 2012-08-06 | ||
| PCT/US2013/053843 WO2014025814A1 (en) | 2012-08-06 | 2013-08-06 | Treatment regimens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018103554A Division JP2018150357A (ja) | 2012-08-06 | 2018-05-30 | 治療レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524474A JP2015524474A (ja) | 2015-08-24 |
| JP2015524474A5 true JP2015524474A5 (enExample) | 2016-10-20 |
Family
ID=50068530
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526649A Ceased JP2015524474A (ja) | 2012-08-06 | 2013-08-06 | 治療レジメン |
| JP2018103554A Pending JP2018150357A (ja) | 2012-08-06 | 2018-05-30 | 治療レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018103554A Pending JP2018150357A (ja) | 2012-08-06 | 2018-05-30 | 治療レジメン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9517254B2 (enExample) |
| EP (1) | EP2879680A4 (enExample) |
| JP (2) | JP2015524474A (enExample) |
| KR (4) | KR20230136142A (enExample) |
| CN (2) | CN106924259A (enExample) |
| AU (2) | AU2013299725A1 (enExample) |
| BR (1) | BR112015002687A2 (enExample) |
| CA (1) | CA2881388A1 (enExample) |
| EA (1) | EA201590349A1 (enExample) |
| HK (2) | HK1211239A1 (enExample) |
| IL (1) | IL237150B (enExample) |
| MX (1) | MX2015001695A (enExample) |
| SG (3) | SG10201709967YA (enExample) |
| WO (1) | WO2014025814A1 (enExample) |
| ZA (1) | ZA201501562B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170142797A (ko) * | 2016-06-17 | 2017-12-28 | 에스원 바이오파머, 인크. | 부프로피온 및 트라조돈 조합 치료를 이용한 여성의 성욕 감퇴 장애（ｈｓｄｄ）의 치료 방법 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2025042884A2 (en) * | 2023-08-21 | 2025-02-27 | Kuleon Llc | Serotonin receptor modulators for the treatment of addictions and overdoses |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
| WO2025245102A2 (en) * | 2024-05-21 | 2025-11-27 | S1 Biopharma, Inc. | Methods and compositions for treating sexual disorder, weight loss, weight maintenance, well-being, and self-esteem |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4687771A (en) | 1985-11-01 | 1987-08-18 | Bristol-Myers Company | Method for treatment of male impotence |
| DE4321965A1 (de) | 1993-07-01 | 1995-01-12 | Cytech Biomedical Inc | Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| JP2002322085A (ja) | 2001-04-26 | 2002-11-08 | Kazuhito Tomizawa | 知的機能障害治療剤 |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| ATE477811T1 (de) * | 2002-10-03 | 2010-09-15 | Neuropharmacology Services Llc | Oxytocin zur behandlung von autismus und asperger-syndrom |
| WO2004078147A2 (en) | 2003-03-05 | 2004-09-16 | Pr Pharmaceuticals | Oxytocin controlled release formulations and methods of using same |
| CN1946404A (zh) | 2004-04-22 | 2007-04-11 | 贝林格尔·英格海姆国际有限公司 | 用于治疗性功能疾病ⅱ的新颖药物组合物 |
| KR20070014184A (ko) | 2004-04-22 | 2007-01-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 성기능 장애 치료용 신규 약제학적 조성물 ⅱ |
| US20060004076A1 (en) | 2004-06-30 | 2006-01-05 | Inflabloc Pharmaceuticals, Inc. | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation |
| US20060122127A1 (en) * | 2004-11-17 | 2006-06-08 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtzapine treatment |
| WO2006096435A1 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
| US9023793B2 (en) * | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| JP2010508354A (ja) * | 2006-10-31 | 2010-03-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 広汎性発達障害の処置 |
| WO2008075162A2 (en) | 2006-12-15 | 2008-06-26 | Pfizer Limited | Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction |
| WO2009016488A2 (en) * | 2007-08-02 | 2009-02-05 | Compugen, Ltd. | Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods |
| US20100048630A1 (en) * | 2008-08-21 | 2010-02-25 | Pradeep Banerjee | Methods for treating cns disorders |
| MX353752B (es) * | 2009-01-20 | 2018-01-26 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Los ácidos sórbico y benzoico y sus derivados aumentan la actividad de un neurofármaco. |
| WO2011140608A1 (en) | 2010-05-14 | 2011-11-17 | Keating Charlotte L | Neuropsychopharmacological treatment regimes for treating psychological disorders |
| WO2011146726A1 (en) * | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders |
| WO2012016229A2 (en) | 2010-07-30 | 2012-02-02 | The Regents Of The University Of California | Oxytocin treatment to improve memory and modify blood glucose |
| EA201391459A1 (ru) | 2011-04-04 | 2014-03-31 | С1 Биофарма, Инк. | Режимы лечения |
-
2013
- 2013-08-06 US US14/420,112 patent/US9517254B2/en active Active
- 2013-08-06 CA CA2881388A patent/CA2881388A1/en not_active Abandoned
- 2013-08-06 MX MX2015001695A patent/MX2015001695A/es unknown
- 2013-08-06 SG SG10201709967YA patent/SG10201709967YA/en unknown
- 2013-08-06 AU AU2013299725A patent/AU2013299725A1/en not_active Abandoned
- 2013-08-06 SG SG10201908587P patent/SG10201908587PA/en unknown
- 2013-08-06 HK HK15112183.5A patent/HK1211239A1/xx unknown
- 2013-08-06 KR KR1020237027646A patent/KR20230136142A/ko not_active Ceased
- 2013-08-06 JP JP2015526649A patent/JP2015524474A/ja not_active Ceased
- 2013-08-06 EA EA201590349A patent/EA201590349A1/ru unknown
- 2013-08-06 HK HK16102368.2A patent/HK1214505A1/zh unknown
- 2013-08-06 EP EP13827390.9A patent/EP2879680A4/en not_active Withdrawn
- 2013-08-06 CN CN201710010422.0A patent/CN106924259A/zh active Pending
- 2013-08-06 SG SG11201500919PA patent/SG11201500919PA/en unknown
- 2013-08-06 KR KR1020257008033A patent/KR20250041078A/ko active Pending
- 2013-08-06 KR KR1020207031031A patent/KR20200128437A/ko not_active Ceased
- 2013-08-06 CN CN201380052215.1A patent/CN104884060A/zh active Pending
- 2013-08-06 BR BR112015002687A patent/BR112015002687A2/pt not_active IP Right Cessation
- 2013-08-06 WO PCT/US2013/053843 patent/WO2014025814A1/en not_active Ceased
- 2013-08-06 KR KR1020157006024A patent/KR20150063039A/ko not_active Ceased
-
2015
- 2015-02-08 IL IL237150A patent/IL237150B/en active IP Right Grant
- 2015-03-06 ZA ZA2015/01562A patent/ZA201501562B/en unknown
-
2018
- 2018-05-30 JP JP2018103554A patent/JP2018150357A/ja active Pending
- 2018-07-11 AU AU2018205121A patent/AU2018205121A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535786A5 (enExample) | ||
| TN2018000121A1 (en) | Valbenazine salts and polymorphs thereof | |
| JP2015501783A5 (enExample) | ||
| JP2018520189A5 (enExample) | ||
| CL2012002175A1 (es) | Composicion farmaceutica oral de liberacion prolongada que comprende un agente activo de fracciones de propargilamina y aminoindano; metodo de preparacion; uso en el tratamiento de enfermedades neurodegenerativas o lesiones en el sistema nervioso tales como parkinson o alzheimer, un accidente cerebrovascular o lesion traumatica cerebral. | |
| JP2017075173A5 (enExample) | ||
| JP2016199576A5 (enExample) | ||
| JP2015523407A5 (enExample) | ||
| JP2015515985A5 (enExample) | ||
| JP2010222367A5 (enExample) | ||
| MX375282B (es) | Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares. | |
| AR070570A2 (es) | Compuesto de arilvinilazacicloalcano, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por alfa4beta2 nachr. | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| CL2012003212A1 (es) | Formas cristalinas i y ii de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado; procedimientos de preparacion; composicion farmaceutica; su procedimiento de preparacion; y su uso para el tratamiento de trastornos tales como trastorno por deficit de atencion y enfermedad de parkinson. | |
| JP2020513032A5 (enExample) | ||
| HRP20180018T1 (hr) | Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja | |
| RU2020115710A (ru) | Терапевтические агенты для нейродегенеративных заболеваний | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| UY36274A (es) | Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g | |
| RU2019138166A (ru) | Средство для профилактики или лечения атрофии головного мозга | |
| JP2016515550A5 (enExample) | ||
| JP2018083843A5 (enExample) |